相关实验视频

Updated: Jun 5, 2026

High-throughput Flow Cytometry Cell-based Assay to Detect Antibodies to N-Methyl-D-aspartate Receptor or Dopamine-2 Receptor in Human Serum

High-throughput Flow Cytometry Cell-based Assay to Detect Antibodies to N-Methyl-D-aspartate Receptor or Dopamine-2 Receptor in Human Serum

Published on: November 23, 2013

在接受Ocrelizumab或Natalizumab治疗的早期高度活跃的复发性缓解多发性硬化症患者中实现NEDA-3

Elisabetta Signoriello¹, Alessio Signori², Giacomo Lus¹

¹Second Division of Neurology, University of Campania Luigi Vanvitelli - Naples, Italy.

Multiple sclerosis and related disorders

|May 8, 2024

概括

在高度活跃的多发性硬化症患者中,使用纳塔利祖马布或奥克雷祖马布开始高效疾病修饰疗法 (HE DMT),可以在三年内实现无疾病活性证据 (NEDA-3),两种治疗的结果相似.

科学领域:

神经学神经学
免疫学免疫学免疫学
临床试验临床试验

背景情况:

早期高效疾病修饰疗法 (HE DMT) 对于管理高度活跃的多发性硬化症 (MS) 至关重要.
纳塔利祖马布 (NAT) 和奥克雷祖马布 (OCR) 是具有强大的抗炎性质的有效的HE DMT.
对于优化治疗策略而言,研究以前未接受过治疗的高度活跃的MS患者的治疗结果至关重要.

研究的目的:

为了比较Natalizumab (NAT) 和Ocrelizumab (OCR) 在达到NEDA-3的有效性,在三年内在以前没有接受过治疗的高度活跃的MS患者中.
评估接受NAT与OCR的患者的疾病活性,残疾恶化的时间和NEDA-3成就.
提供关于在早期阶段的成员国启动HE DMT的长期益处的见解.

主要方法:

对接受NAT或OCR.治疗的高活跃多发性硬化患者的回顾性招募.
收集治疗前后的人口,临床和仪器数据.
倾向性评分分析,以比较治疗组之间的疾病活性,残疾恶化的时间和NEDA-3成就.

主要成果:

总共分析了281名高度活跃的MS患者 (157名NAT,124名OCR).
三年后,通过OCR实现NEDA-3的概率为66.0%,使用NAT的概率为68.2%.
在NAT和OCR组之间没有观察到NEDA-3成就的显著差异 (p = 0.27).

结论:

在高度活跃的MS患者中,用NAT或OCR等单克隆抗体启动HE DMT可能会导致NEDA-3的高发病率.
在这种患者群体中,纳塔利祖马布和奥克雷祖马布在三年内实现NEDA-3的有效性相似.
这些发现支持在高度活跃的MS的管理中早期使用HE DMT,以防止神经损伤.

关键词:

高效疾病修饰疗法 (HE DMTs) 是一种高效的疾病修饰疗法.高活跃多发性硬化症患者 (HAMS)多发性硬化症是一种多发性硬化症.在NEDA-3中,它是NEDA-3.娜塔莉莎表示这就是Ocrelizumab.

更多相关视频

A Method of Trigonometric Modelling of Seasonal Variation Demonstrated with Multiple Sclerosis Relapse Data

A Method of Trigonometric Modelling of Seasonal Variation Demonstrated with Multiple Sclerosis Relapse Data

Published on: December 9, 2015

Induction and Diverse Assessment Indicators of Experimental Autoimmune Encephalomyelitis

Induction and Diverse Assessment Indicators of Experimental Autoimmune Encephalomyelitis

Published on: September 9, 2022

相关概念视频

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents

Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel Disease...

Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids

Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids

Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2 (COX-2),...

Chemotherapy-Induced Nausea and Vomiting: 5-HT3 Receptor Antagonists

Chemotherapy-Induced Nausea and Vomiting: 5-HT₃ Receptor Antagonists

5-HT3 receptor antagonists, such as dolasetron, granisetron (Kytril), ondansetron (Zofran), and palonosetron (Axoli), are crucial in managing chemotherapy-induced nausea and vomiting (CINV) and postoperative nausea. These drugs selectively block 5-HT3 receptors in the visceral vagal and spinal afferent nerves, chemoreceptor trigger zone, and the vomiting center. They have a rapid onset of action and can be given as a single dose before chemotherapy. Ondansetron and granisetron, in particular,...

Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists

Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists

Neurokinin 1 (NK1) receptors are distributed across the GI tract, vagal afferents, and key CNS regions including the central vomiting center and chemoreceptor trigger zone (CTZ) Chemotherapy agents stimulate enterochromaffin cells in the gastrointestinal (GI) tract to release large amounts of substance P (SP). SP is a neuropeptide released by specific sensory nerves in response to many different stressors, including those in the GI mucosa affected by chemotherapy. SP binds and activates these...

Chemotherapy-Induced Nausea and Vomiting: Dopamine Receptor Antagonists

Chemotherapy-Induced Nausea and Vomiting: Dopamine Receptor Antagonists

Dopamine receptor antagonists, also known as antipsychotic agents, are critical in managing chemotherapy-induced vomiting. These antiemetic agents block dopamine receptors in the chemoreceptor trigger zone (CTZ), inhibiting signal transmission to the vomiting center. Antipsychotic agents encompass phenothiazines (PTZ), butyrophenones, benzamides, and thienobenzodiazepines (Zyprexa), which are utilized for their antiemetic and sedative properties.
Phenothiazines, such as prochlorperazine...

Nephrotic Syndrome III : Nursing Management

Nephrotic Syndrome III : Nursing Management

Nursing management for nephrotic syndrome adapts as the disease progresses, with strategies evolving to address advancing symptoms and complications.Early-Stage Management In the early stages, nursing interventions for nephrotic syndrome resemble those used in managing acute glomerulonephritis, focusing on symptom monitoring, fluid balance, and managing mild to moderate edema.Vital Signs: Regularly monitor blood pressure, pulse, respiratory rate, and temperature to promptly identify...